J&J medtech miss overshadows earnings beat

Johnson & Johnson said on Wednesday that its medical device unit underperformed in the second quarter, even as strong sales of Tremfya for autoimmune conditions and cancer treatment Darzalex helped it beat Wall Street estimates. U.S. demand for its Impella heart pumps, acquired through its **$16.6 billion** 2022 buyout of Abiomed, dropped in the second quarter by **2%** after having grown **14%** during the first quarter, the company said. CFO Joseph Wolk said in an interview that Abiomed revenue took a hit following the release of a UK study that raised questions about the use of Impella pumps during certain high-risk coronary procedures. Wolk said J&J expects the franchise to return to growth, aided by additional data expected in the first half of next year that could further demonstrate the usefulness of the pumps. "When you have 28 platforms that generate at least $1 billion in revenue on an annual basis, we're not dependent on one asset," Wolk said. Shares of the company closed **2.7% lower** at **$247.02**. Still, the company said it is not seeing evidence of a slowdown of procedures using its medical devices after hospital operator HCA Healthcare warned on Tuesday of weaker surgical volumes and more patients dropping out of Affordable Care Act plans. That pushed shares down in J&J and other medtech companies such as Stryker and Intuitive Surgical. "Procedure volumes continue to be stable," J&J Executive Vice President Tim Schmid said in a conference call with investors. "We have not observed any meaningful impact on procedure volumes across our portfolio related to the ACA." Sales at J&J's medtech unit came in at **$8.93 billion**, below analysts' average estimate of **$8.97 billion**, according to data compiled by LSEG. "Overall medtech procedures were solid as shown by strength in ortho, vision and stability in surgery," Evercore ISI analyst Vijay Kumar said. Kumar said the results could help ease concerns around broad demand for medical devices. J&J's second-quarter sales grew nearly **7%** to **$25.31 billion**, above analysts' average estimate of about **$25.05 billion**. The pharmaceutical unit helped boost total sales. It generated **$16.38 billion** in quarterly sales, ahead of analysts' estimate of **$16.1 billion**. Adjusted earnings per share stood at **$2.90**, topping an expectation of **$2.85**. The company now expects annual sales of about **$101.1 billion** at the midpoint, compared with **$100.8 billion** previously. It also raised its adjusted earnings per share forecast to **$11.68** at the midpoint, from **$11.55** per share previously. Sales of its psoriasis and inflammatory bowel disease drug, Tremfya, jumped **72.5%** to **$2 billion**, well above the estimate of **$1.74 billion**. Tremfya has become increasingly important as J&J works to replace lost sales from Stelara. Revenue from Stelara, which treats psoriasis, Crohn's disease and other autoimmune conditions, fell more than **55%** to **$740 million** in the quarter.

J&J medtech miss overshadows earnings beat

Medtech miss weighs on results

Procedure volumes and medtech demand remain stable

Forecast raised after stronger pharmaceutical sales

Related News

Nasdaq trade halt <TNON.O> halt news pending at 07:50 PM

NexGen publishes corporate presentation highlighting Rook I uranium project construction progress

I Squared Capital beneficial owner ISQ Global Fund II GP reports Kinetik Holdings share disposal worth $13.26 million

Trump-linked fintech AI Financial sells unit to Prime Delta

Iran says 'very close' to Oman deal on temporary Strait of Hormuz shipping route